Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the sale, the executive vice president now owns 64,613 shares of the company’s stock, valued at approximately $4,772,962.31. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Gilead Sciences, Inc. (NASDAQ:GILD) traded down $0.76 during trading hours on Thursday, hitting $73.90. 4,980,000 shares of the company’s stock traded hands, compared to its average volume of 7,450,000. The firm has a market capitalization of $96,510.00, a P/E ratio of 8.41, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.75 earnings per share. research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio (DPR) is 23.66%.

GILD has been the subject of a number of recent analyst reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada initiated coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target for the company. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $85.03.

Several large investors have recently bought and sold shares of GILD. Spears Abacus Advisors LLC lifted its position in shares of Gilead Sciences by 96.8% during the 1st quarter. Spears Abacus Advisors LLC now owns 320,770 shares of the biopharmaceutical company’s stock worth $21,787,000 after purchasing an additional 157,752 shares during the last quarter. Glenview Trust Co lifted its position in shares of Gilead Sciences by 1.1% during the 1st quarter. Glenview Trust Co now owns 123,204 shares of the biopharmaceutical company’s stock worth $8,368,000 after purchasing an additional 1,375 shares during the last quarter. Herndon Capital Management LLC lifted its position in shares of Gilead Sciences by 31.1% during the 1st quarter. Herndon Capital Management LLC now owns 313,915 shares of the biopharmaceutical company’s stock worth $21,321,000 after purchasing an additional 74,417 shares during the last quarter. ARS Investment Partners LLC lifted its position in shares of Gilead Sciences by 0.9% during the 1st quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 50 shares during the last quarter. Finally, Jupiter Asset Management Ltd. purchased a new stake in shares of Gilead Sciences during the 1st quarter worth $2,792,000. Institutional investors and hedge funds own 75.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/04/gregg-h-alton-sells-15000-shares-of-gilead-sciences-inc-gild-stock.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply